OPRX icon

OptimizeRx

12.97 USD
-1.02
7.29%
At close Jul 18, 3:59 PM EDT
After hours
13.23
+0.26
2.00%
1 day
-7.29%
5 days
2.37%
1 month
-0.92%
3 months
54.77%
6 months
139.74%
Year to date
148.94%
1 year
27.41%
5 years
-16.21%
10 years
24.71%
 

About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Employees: 129

0
Funds holding %
of 7,321 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

84% more capital invested

Capital invested by funds: $55.3M [Q4 2024] → $102M (+$46.4M) [Q1 2025]

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

1.74% more ownership

Funds ownership: 61.72% [Q4 2024] → 63.47% (+1.74%) [Q1 2025]

0% more funds holding

Funds holding: 87 [Q4 2024] → 87 (+0) [Q1 2025]

11% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 27

61% less call options, than puts

Call options by funds: $1.02M | Put options by funds: $2.62M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$14
8%
upside
Avg. target
$15
16%
upside
High target
$16
23%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
David Grossman
23%upside
$16
Buy
Maintained
9 Jun 2025
JMP Securities
Constantine Davides
8%upside
$14
Market Outperform
Maintained
13 May 2025

Financial journalist opinion

Based on 10 articles about OPRX published over the past 30 days

Positive
Zacks Investment Research
6 hours ago
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
Neutral
GlobeNewsWire
1 day ago
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call.
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
Neutral
Zacks Investment Research
2 days ago
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
Positive
Zacks Investment Research
1 week ago
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
Positive
Zacks Investment Research
1 week ago
Best Growth Stocks to Buy for July 9th
OPRX, EWCZ and QFIN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 9, 2025.
Best Growth Stocks to Buy for July 9th
Neutral
Zacks Investment Research
2 weeks ago
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
Positive
Zacks Investment Research
2 weeks ago
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
Positive
Zacks Investment Research
3 weeks ago
Best Growth Stocks to Buy for June 25th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today June 25th:
Best Growth Stocks to Buy for June 25th
Neutral
GlobeNewsWire
3 weeks ago
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025.
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
Neutral
Business Wire
1 month ago
Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions
CANNES, France--(BUSINESS WIRE)-- #TV--Simulmedia announced a strategic partnership with OptimizeRx Corp. to enable the self-serve availability of Micro-Neighborhood® Targeting (MNT).
Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions
Charts implemented using Lightweight Charts™